ACE inhibition in secondary prevention: Are the results controversial?

Clinical Research in Cardiology

Volumn 95, Issue 2, 2006, Pages 61-67

  Friedrich, E B ^a   Teo, K K ^b   Bohm M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

ACE inhibitors; Coronary artery disease; EUROPA; HOPE; PEACE; Secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SOLUBILITY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIPOPHILICITY; LOW DRUG DOSE; MORTALITY; PATHOPHYSIOLOGY; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR FUNCTION, LEFT;

EID: 33144462795     PISSN: 18610684     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-006-0334-6     Document Type: Article

References (18)

1. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435
2. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302
3. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691
4. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828
5. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360:752-760
6. The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153
7. Fox KM. The EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre rial (the EUROPA study). Lancet 362:782-788
8. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson B, Fihn SD, Fraker TD, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article. Circulation 107:149-158
9. The PEACE Trial Investigators (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351:2058-2068
10. Mancini GB, Henry GC, Macaya C et al (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 94:258-265
11. Anderson RN, Smith BL (2003) Deaths: leading causes for 2001. Natl Vital Stat Rep 52:1-86
12. Yusuf S (2005) ACE inhibition in stable coronary artery disease [corresponence]. N Engl J Med 352:937-939
13. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E (2004) Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 141:102-112
14. Brown NJ, Vaughan DE (1998) Angiotensin-converting enzyme inhibitors. Circulation 97:1411-1420
15. Lonn EM, Yusuf S, Dzavik V, Doris I, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK, for the SECURE Investigators (2001) Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 103:919-925
16. Marre M, Lievre M, Chatellier G, Mann JFE, Passa P, Ménard J, on behalf of the DIABHYCAR Study Investigators (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double-blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495-501
17. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670-1676
18. The ONTARGET/TRANSCEND Investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Am Heart J 148:52-61